Incretin & metabolic research compounds
Dulaglutide
Also known as Trulicity
A once-weekly GLP-1 receptor agonist made by fusing two GLP-1 analogues to an antibody Fc fragment.
In 60 seconds
Approved for type 2 diabetes; the REWIND cardiovascular-outcomes trial is its landmark dataset. Class gastrointestinal effects; REWIND exploratory analyses also examined renal and cognitive outcomes.
- REWIND measured major adverse cardiovascular events with dulaglutide versus placebo in type 2 diabetes.
- Reviews dulaglutide’s trial and real-world evidence as a weekly GLP-1 receptor agonist.
- An exploratory REWIND analysis examined dulaglutide and cognitive impairment.
Mechanism
Dulaglutide’s Fc fusion gives it a large size and slow clearance, allowing weekly dosing at the GLP-1 receptor with the class’s glucose-dependent insulin and glucagon effects.
Research status
Approved for type 2 diabetes; the REWIND cardiovascular-outcomes trial is its landmark dataset.
Key studies
REWIND measured major adverse cardiovascular events with dulaglutide versus placebo in type 2 diabetes.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial — Lancet, 2019 · PMID 31189511
Reviews dulaglutide’s trial and real-world evidence as a weekly GLP-1 receptor agonist.
Dulaglutide: A Review in Type 2 Diabetes — Drugs, 2020 · PMID 32002850
An exploratory REWIND analysis examined dulaglutide and cognitive impairment.
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial — Lancet Neurol, 2020 · PMID 32562683
A meta-analysis comparing semaglutide with liraglutide, dulaglutide and tirzepatide.
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis — Front Pharmacol, 2025 · PMID 40444045
Safety signals in the literature
Class gastrointestinal effects; REWIND exploratory analyses also examined renal and cognitive outcomes.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Dulaglutide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Dulaglutide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Dulaglutide?
A once-weekly GLP-1 receptor agonist made by fusing two GLP-1 analogues to an antibody Fc fragment. Dulaglutide’s Fc fusion gives it a large size and slow clearance, allowing weekly dosing at the GLP-1 receptor with the class’s glucose-dependent insulin and glucagon effects.
What is the research status of Dulaglutide?
Approved for type 2 diabetes; the REWIND cardiovascular-outcomes trial is its landmark dataset.
What safety signals are reported for Dulaglutide?
Class gastrointestinal effects; REWIND exploratory analyses also examined renal and cognitive outcomes.
Does Living Water Labs stock Dulaglutide?
Not at present. Dulaglutide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
